BioSpace News Archive

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, provided a business and financial update for the first quarter 2023.

Adicet Bio, Inc. (Nasdaq: ACET) today announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 JMP Securities Life Sciences Conference being held from May 15-16, 2023 in New York.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, reported financial results for the quarter ended March 31, 2023.

Curesponse, a commercial-stage precision oncology company, presented preliminary clinical results from a multi-center UK Study at the American Association for Cancer Research meeting in Orlando, Florida.

Theranexus and the Beyond Batten Disease Foundation, have announced receipt of approval from the Food and Drug Administration for the design and primary and secondary endpoints of the pivotal Phase III trial for Batten disease CLN3, at a meeting with the Division of Rare Diseases and Medical Genetics held in mid-April.

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, announced the appointment of Cynthia Collins to the company’s board of directors.

Evotec SE and Sandoz AG, a division of Novartis announced that Evotec’s Seattle-based subsidiary, Just - Evotec Biologics, Inc., launched a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars.

Prometheus Biosciences, Inc., a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, reported financial results for the quarter ended March 31, 2023.

Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, reported financial results for the first quarter ended March 31, 2023 and provided corporate updates.

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.